Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has captured the attention of analysts at Rodman & Renshaw, who initiated coverage with a 'Buy' rating and an $8.00 price target. The firm's valuation reflects the potential of Lucid-MS, a drug candidate described as a potentially first-in-class non-immunomodulatory small molecule. Lucid-MS is being developed to address neurodegeneration and disability progression in progressive multiple sclerosis (MS), a condition where therapeutic options remain notably limited.
The significance of this rating lies in the urgent need for treatments that can slow or halt the progression of MS, particularly in its progressive forms. Current therapies primarily target relapsing forms of the disease and often fail to prevent long-term disability. Lucid-MS, if successful, could offer a new mechanism of action that directly targets the underlying neurodegeneration, a key driver of disability accumulation. This differentiates it from existing immunomodulatory drugs and positions it as a potential breakthrough in a challenging therapeutic area.
The $8.00 price target set by Rodman & Renshaw underscores the potential upside for investors, but also hinges on successful clinical development. Quantum BioPharma is advancing Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc. Preclinical models have shown that Lucid-MS can prevent and reverse myelin degradation, which is the underlying mechanism of MS. These promising results have generated optimism, but the drug's true potential will be tested in rigorous clinical trials to establish safety and efficacy in humans.
Beyond Lucid-MS, Quantum BioPharma is building a broader pipeline targeting neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company has also spun out its OTC product UNBUZZD(TM) into Unbuzzd Wellness Inc. (UWI), retaining a 19.48% ownership stake as of June 30, 2026, and standing to receive royalty payments from sales. This diversified approach may mitigate some of the inherent risks in biotech development.
The 'Buy' rating from Rodman & Renshaw is a notable endorsement for Quantum BioPharma, potentially increasing visibility among institutional investors. However, investors should consider the inherent risks of biotechnology investing, including clinical trial failures and regulatory hurdles. The company's ability to execute its development plans for Lucid-MS will be critical in realizing the value implied by the analyst's price target.
For more information on Lucid-MS, visit https://nnw.fm/8uqwL. For the latest news and updates on Quantum BioPharma, refer to the company's newsroom at https://nnw.fm/QNTM.
